CoChat
Sign Up
Cited by 80Extracellular vesicles in diseaseParkinson's Disease Mechanisms and TreatmentsMicroRNA in disease regulation

Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease

Open access
He, Shulei, Huang, Lu, Shao, Ci, Nie, Tiejian, Xia, Li, Cui, Bozhou, Lu, Fangfang, Zhu, Lin +2 more·2021·Translational Neurodegeneration
DOI 10.1186/s40035-021-00249-yPMC PMC8317324

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Blood-based test for predicting disease progression and early diagnosis of Parkinson’s disease (PD) is an unmet need in the clinic. The profiles of microRNAs (miRNAs) are regarded as potential diagnostic biomarkers for human diseases, whereas miRNAs in the periphery are susceptible to the influence of various components. MiRNAs enriched in serum extracellular vesicles (EVs) have demonstrated disease-specific advantages in diagnosis due to their high abundance, stability and resistance to degradation. This study was aimed to screen differentially expressed EV-derived miRNAs between healthy controls and PD patients to aid in diagnosis of PD. Methods: A total of 31 healthy controls and 72 patients with a diagnosis of PD at different Hoehn and Yahr stages in Tangdu Hospital were included. In total, 185 differentially expressed miRNAs were obtained through RNA sequencing of serum EVs as well as edgeR and t -test analyses. Subsequently, the weighted gene co-expression network analysis (WGCNA) was utilized to identify the commonly expressed miRNAs in all stages of PD by constructing connections between modules, and specifically expressed miRNAs in each stage of PD by functional enrichment analysis. After aligning these miRNAs with PD-related miRNAs in Human miRNA Disease Database, the screened miRNAs were further validated by receiver operating characteristic (ROC) curves and quantitative real-time polymerase chain reaction (qRT-PCR) using peripheral blood EVs from 40 more participants. Results: WGCNA showed that 4 miRNAs were commonly associated with all stages of PD and 13 miRNAs were specifically associated with different stages of PD. Of the 17 obtained miRNAs, 7 were validated by ROC curve analysis and 7 were verified in 40 more participants by qRT-PCR. Six miRNAs were verified by both methods, which included 2 miRNAs that were commonly expressed in all stages of PD and 4 miRNAs that were specifically expressed in different stages of PD. Conclusions: The 6 serum EV-derived miRNAs, hsa-miR-374a-5p, hsa-miR-374b-5p, hsa-miR-199a-3p, hsa-miR-28-5p, hsa-miR-22-5p and hsa-miR-151a-5p, may potentially be used as biomarkers for PD progression and for early diagnosis of PD in populations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40035-021-00249-y

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • hsa-miR-374a-5p, hsa-miR-374b-5p, hsa-miR-199a-3p, hsa-miR-28-5p, hsa-miR-22-5p, and hsa-miR-151a-5p could be potential biomarkers in serum EVs for Parkinson's disease prognosis and diagnosis.

    “The research concluded that hsa-miR-374a-5p, hsa-miR-374b-5p, hsa-miR-199a-3p, hsa-miR-28-5p, hsa-miR-22-5p, and hsa-miR-151a-5p could be potential biomarkers in serum EVs for PD prognosis and diagnosis [153].”

    From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [153]

    The Conclusions (page not specified) identify all six serum EV-derived miRNAs as potential biomarkers for early PD diagnosis and disease progression. The paper assesses differences between disease stages, but does not establish that the miRNAs predict future outcomes; the claim’s use of “prognosis” goes beyond that evidence. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
He, S., Huang, L., Shao, C., Nie, T., Xia, L., Cui, B., Lu, F., Zhu, L., Chen, B., & Yang, Q.
Affiliations
  • Tang Du Hospital (CN)
  • Northwestern Polytechnical University (CN)
Corresponding author
  • Chen, Bolin
  • Yang, Qian
ORCID
Venue
Translational Neurodegeneration
Publisher
Springer Science and Business Media LLC
Published
2021-07-28
Volume
10
Issue
1
Pages
25-25
ISSN
2047-9158 (ISSN-L)
DOI
10.1186/s40035-021-00249-y
PMC
PMC8317324
OpenAlex
W3186270220
Cited by
80
References
46
Citations by year
2026: 7 · 2025: 19 · 2024: 21 · 2023: 18 · 2022: 15
FWCI
4.24
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational Neurodegeneration (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (Grant No. 31930048 (Q.Y), Grant No. 31671060 (Q.Y), Grant No. 61972320 (B. C))
  • the Projects of International Cooperation and Exchange NSFC (Grant No. 81720108016 (Q.Y))
  • The National Key Research and Development Program of China (Grant No. 2016YFC1306603 (Q.Y))
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
Parkinson's disease, serum extracellular vesicles, microRNA, diagnostic biomarkers, disease progression, Hoehn and Yahr stage, blood-based diagnosis
MeSH terms
Extracellular Vesicles, Aged, Female, Genetic Testing, Humans, Male, Middle Aged, Parkinson Disease, Biomarkers, Sequence Analysis, RNA, MicroRNAs, Early Diagnosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review